Lilly's oral GLP-1 just cleared a heart-safety bar. Now comes the part nobody puts in the headline: how high was that bar? GLP-1 Daily, Friday edition. Also ahead: where the FDA draws the line between compounding and copying, and who's watching out for the people actually enrolled in obesity trials. Pill first. Actually, quick detour first. The FDA says Empower Pharmacy made an “inordinate” number of copies of weight-loss drugs. But if compounding can be legal for an individual patient, where does the agency draw the line? Basically, it comes down to whether a pharmacy's preparing a medication for a patient's documented individual need, or effectively churning out a version of an FDA-approved drug at scale. The FDA's September warning letter to Empower Clinic Services, doing business as Empower Pharmacy, focused on compounded semaglutide and tirzepatide combination products. It also zeroed in on the pharmacy's production volume, its prescription records, and its relationships with third-party prescribing platforms. Legal analyses of the letter say the agency looked at whether prescribers had made and documented a “significant difference” determination for particular patients. And adding an ingredient like vitamin B12 or niacinamide doesn't automatically make a product different enough. According to those analyses, the FDA concluded the combinations at issue were still “essentially copies” of approved products. One caveat, as LumaLex Law notes: a warning letter states the agency's position after an inspection, and it isn't an adjudication. If you're a patient, don't change treatment on your own because of this. Ask your prescriber and pharmacy what individualized difference the compounded prescription is meant to address, and how that's documented. So a label listing an added vitamin isn't, by itself, proof that the prescription's a lawful individualized compound? That's the practical takeaway from the FDA's position here. The agency looked past the ingredient list to whether there was a real, documented patient-specific reason, and whether the operation looked like mass copying. Patients can ask whether the pharmacy is a 503A facility, who wrote the prescription, and what specific difference from the FDA-approved medicine their prescriber has identified. Those answers won't settle the legal question, but they'll make for a better-informed conversation with your prescriber and pharmacy. Here's Emma Koehn at The Limbic:
The once-daily oral GLP-1RA orforglipron does not show any excess cardiovascular risks when compared with insulin glargine for patients with type 2 diabetes, data presented at the European Association for the Study of Diabetes 2026 meeting has shown. Highly anticipated results from the ACHIEVE-4 trial, presented in Milan last week, confirmed the CVD safety of the drug, a hurdle that had to be cleared for developer Lilly to progress with registration of the therapy in future.
Okay, now the pill. ACHIEVE-4, now in The Lancet: oral orforglipron versus insulin glargine, 2,749 people with type 2 diabetes, more than 85 percent with established heart disease. Hazard ratio of 0.84 on four-point MACE, which gets you noninferiority. No excess risk. Full stop. And the lower death numbers in the orforglipron arm? Not powered for it. Even Gian Paolo Fadini's independent read at EASD said you can't call this cardioprotective. It's a safety box Lilly needed checked, and per The Incretins it clears the FDA and EMA hurdle. That's the headline. Okay, but look at who cleared it. Type 2, long-duration, nearly 38 percent with kidney disease. So the first label this supports is a diabetes label, and a pill with a diabetes code is the same door the cash-pay obesity patient already can't walk through. Registration and coverage are two different finish lines. This one's from EXA:
So trials of obesity pharmacotherapies have largely been designed with change in BMI as the primary endpoint and a goal of maximizing weight loss. So my concern is that these trials aren't built to detect the harms that have become more likely as obesity pharmacotherapy is becoming more and more effective.
Sarah Schmitz, obesity medicine at Weill Cornell, wrote an NEJM perspective, and her argument's simple. These trials are built around BMI change, and they chase maximum weight loss. So they aren't designed to catch the harms that get more likely as the drugs get stronger. And 'stronger' is literal. She points to retatrutide: more than twenty-four percent weight loss in under a year in phase two, with phase three top-lines approaching bariatric surgery territory. Which is the pitch. It's also her worry. The orforglipron trial we just hit was purpose-built to find one specific harm, heart risk, and it did its job. Nobody's built the equivalent for nutrition or physical function. As a patient, I want to know what I'm consenting to lose besides weight. Quick caveat first: this is one physician's argument, and nobody's reported a safety signal here. But I'd add a question. Who's actually enrolled in these trials? Whatever they don't measure, the patients left out will inherit later, unmeasured. Right, and if the trials won't look, post-market surveillance has to. And it needs real requirements attached. A polite request won't cut it. If you're enjoying GLP-1 Daily, please subscribe and leave us a review wherever you're listening. Reviews help other people find the show, and we're really glad to have you with us.
Links to every story are in the show notes, so dig into whatever caught your attention, at your own pace.
That's GLP-1 Daily for today. We'll be back with the next episode on Monday. This is a Lantern Podcast.